Liver fibrosis may be diagnosed and staged — no fibrosis (stage F0), mild fibrosis (F1), significant fibrosis (F2), advanced fibrosis (F3), and cirrhosis (F4) — with the use of clinical parameters and ...
Enhanced Liver Fibrosis (ELF™) Test Gauges Likelihood of Disease Progression; Expands Labcorp’s Testing Options for Nonalcoholic Fatty Liver Disease The ELF test provides a numeric score to people ...
SAN DIEGO — Semaglutide, a glucagon-like peptide 1 (GLP-1) receptor agonist, appears to safely and effectively treat metabolic dysfunction–associated steatohepatitis (MASH) among patients with ...
(RTTNews) - Altimmune Inc. (ALT) announced that its investigational dual glucagon/GLP-1 receptor agonist, pemvidutide, achieved statistically significant improvements in non-invasive markers of liver ...
MedPage Today brought together three hepatology experts for a virtual roundtable discussion on metabolic dysfunction-associated steatohepatitis (MASH): Moderator Sobia Laique, MD, of the Cleveland ...
GAITHERSBURG, Md., Dec. 19, 2025 (GLOBE NEWSWIRE) -- Altimmune, Inc. (ALT) (Nasdaq: ALT), a late clinical-stage biopharmaceutical company developing therapies that address serious liver diseases, ...
This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Scott Isaacs, MD: ...
WASHINGTON -- Elafibranor (Iqirvo) was well tolerated and led to sustained improvements in liver enzyme levels and itch severity through 28 weeks in patients with primary sclerosing cholangitis (PSC), ...
If your diagnosis of metabolic dysfunction-associated steatotic liver disease (MASLD) came as a surprise, you're not alone. Usually, you're diagnosed after a routine blood test shows higher than ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results